Abstract
About 30% of patients with schizophrenia do not respond to antipsychotic drugs. The authors showed that chronic administration of atypical antipsychotics downregulates metabotropic glutamate 2 receptor (mGlu2) expression in the frontal cortex in mice and in patients with schizophrenia, and this was due to a serotonin receptor 2A-dependent increase in histone deacetylase 2 (Hdac2) expression and HDAC2 binding to the mGlu2 promoter. Chronic administration of HDAC inhibitors improved the effects of antipsychotic drugs in a mouse model of schizophrenia, pointing to their potential clinical use in treatment-resistant schizophrenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
